Corcept Therapeutics

The stock of Corcept Therapeutics rose to an all-time high of $122.50 and is currently trading at $121.31, corresponding to a market capitalization of $13.13 billion. In the second quarter of 2026 the company reported revenue of $256.1 million (+32% year-on-year) and raised its full-year guidance to $1.1–1.2 billion. Analysts responded with price-target increases and positive assessments, while InvestingPro currently rates the stock as overvalued relative to its fair value. » More on de.investing.com

Shares of Corcept Therapeutics rose to a 52-week high of $95.18, gaining 152% over the past six months and 163% year-to-date. The company has resubmitted the New-Drug-Application for Relacorilant to the FDA for the treatment of Cushing’s syndrome; the review is expected to take six months. At ASCO, Corcept presented data from the phase‑3 ROSELLA study showing a 35% reduction in risk of death with Lifyorli (Relacorilant) plus nab‑paclitaxel. First-quarter 2026 revenues of about $165 million were below consensus, but analysts still raised price targets and reiterated buy ratings. » More on de.investing.com

Corcept resubmitted the New Drug Application for relacorilant to the FDA and included additional analyses of the originally requested data. The company expects a six-month review period; the submission is based on data from the GRACE study, the phase III GRADIENT study, a long-term extension and earlier development phases. According to Corcept, relacorilant improves symptoms of Cushing's syndrome without certain side effects, received orphan-drug status and is also already FDA-approved as Lifyorli for platinum-resistant ovarian cancer. Investors reacted positively; the stock is up about 141% year-to-date and the company has a market capitalization of $8.79 billion. » More on de.investing.com